Get notified when AMIX files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsRed Flags Detected
- Going Concern (worsened) — Company disclosed substantial doubt about ability to continue as a going concern for the first time in FY2026, citing $67.1M accumulated deficit and $12.3M operating cash burn.
- Material Weakness (unchanged) — Material weaknesses in segregation of duties, technology controls, and financial reporting persist from prior year with no remediation disclosed.
Autonomix pauses trial after mixed results, adds going-concern warning, extends runway to Q4 2026
Filed May 27, 2026 · Period ending March 31, 2026 · Compared to 10-K May 29, 2025 · ~1 min read
Key Changes
-
high
Clinical trial enrollment paused after PoC 2 showed variable outcomes diverging from initial PoC 1 results; revised protocol now focuses only on severe pancreatic cancer pain, approved April 2026.
Business: Clinical Trial Pause verify on EDGAR → -
high
Going-concern warning added for first time: accumulated deficit $67.1M, operating cash burn $12.3M (up 48%), working capital down to $5.9M. Cash runway extended to Q4 2026 via $10M equity raises.
MD&A: Going Concern verify on EDGAR → -
high
Nasdaq deficiency notice received January 2026 for bid price below $1.00; company has until July 13, 2026 to cure or face potential delisting. Reverse split possible.
Risk Factors: Nasdaq Delisting verify on EDGAR →
2 more material changes behind this preview — plus the full narrative summary, section-by-section diffs against the prior filing, and verbatim quotes with EDGAR citations.
Want to see a complete report first? Today's free report (ADMT 10-K) is open in full — no account needed.
Partner
Trade AMIX commission-free
Open an account, get a free stock.
Investing involves risk. Free stock terms apply.
Thanks — your feedback helps us improve report quality.
Source-verified from EDGAR · Narrative written by AI · May 29, 2026 · How we verify